Skip to main content Skip to main navigation menu Skip to site footer

Immunohistochemical examination of recurrence and giant cell tumor specificity, is it correlated? cohort retrospective study

Abstract

Link of Video Abstract: https://youtu.be/h3ku5ujtEY4

 

Introduction: GCT is a benign tumor that has an aggressive local character. GCT recurrence after disinfection still often occurs. The reasons for treatment failure and triggering a recurrence are believed to be the role of the accumulation of stem cells in promoting tumor initiation and recurrence.

Methods: Study Cohort Retrospective cohort in patients who had undergone surgery with a diagnosis of GCT at RSUPN Dr. Cipto Mangunkusumo in 2017-2022. The subjects were separated into two groups, recurrence patients and non-recurrence patients. The tissue biopsy will be assessed with ALCAM+, Oct4, and Stro-1 biomarkers for tumor stem cells.

Results: A total of 38 patients were diagnosed with Giant Cell Tumor. There were 31.6% of recurrent patients with an age range between 31-40 years and 41-50 years. The most common location is the Distal Radius with a score of 41.7% in recurrent patients and 38.5% in non-recurrent patients. Based on the data, the expression of ALCAM+, OCT4 and Stro-1 did not have significant differences between the two groups. The Recurrence group in p63 was expressed more than in the Non-Recurrence group p=0.002. In CD147, the Recurrence group was also expressed more than in the Non-Recurrence group p=0.003

Conclusion: Increased expression of ALCAM+, OCT4, and Stro-1 occurred in Recurrence and Non-Recurrence patients, although Stro-1 appeared to be more sensitive in detecting GCT progression, but was not statistically different. CD147 and p63 are statistically different between recurrence and non-recurrence.

References

  1. Turcotte RE. Giant Cell Tumor of Bone. Orthopedic Clinics of North America. 2006;37(1):35–51. Available from: http://dx.doi.org/10.1016/j.ocl.2005.08.005
  2. Sobti A, Agrawal P, Agarwala S, Agarwal M. )2( CURRENT CONCEPTS REVIEW Giant Cell Tumor of Bone-An Overview [Internet]. Vol. 4, Arch Bone Jt Surg. 2016. Available from: http://abjs.mums.ac.irtheonlineversionofthisarticleabjs.mums.ac.ir
  3. Fletcher CDM, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. IARC Press; 2013. 468 p.
  4. López-Pousa A, Broto JM, Garrido T, Vázquez J. Giant cell tumour of bone: new treatments in development. Vol. 17, Clinical and Translational Oncology. Springer-Verlag Italia s.r.l.; 2015. p. 419–30.
  5. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant Cell Tumor of Bone. Journal of the American Academy of Orthopaedic Surgeons. 2013;21(2):118–26. Available from: http://dx.doi.org/10.5435/jaaos-21-02-118
  6. Fauzi A. Penilaian Efektivitas dan Sitotoksisitas Terapi Adjuvan Kimia Lokal pada Giant Cell Tumor Tulang secara In Vitro [Internet]. 2018. Available from: https://scholar.ui.ac.id/en/projects/penilaian-efektivitas-dan-sitotoksisitas-terapi-adjuvan-kimia-lok
  7. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR. Giant Cell Tumor of Bone: Review, Mimics, and New Developments in Treatment. RadioGraphics. 2013;33(1):197–211. Available from: http://dx.doi.org/10.1148/rg.331125089
  8. War AR, Dang K, Jiang S, Xiao Z, Miao Z, Yang T, et al. Role of cancer stem cells in the development of giant cell tumor of bone. Cancer Cell Int. 2020;20:135. Available from: https://pubmed.ncbi.nlm.nih.gov/32351329
  9. Georgiev GP, Slavchev S, Dimitrova I, Landzhov B. Giant cell tumor of bone: current review of morphological, clinical, radiological, and therapeutic characteristics. Journal of Clinical and Experimental Investigations. 2014;5(3). Available from: http://dx.doi.org/10.5799/ahinjs.01.2014.03.0445
  10. Gortzak Y, Kandel R, Deheshi B, Werier J, Turcotte RE, Ferguson PC, et al. The efficacy of chemical adjuvants on giant-cell tumour of bone. J Bone Joint Surg Br. 2010;92-B(10):1475–9. Available from: http://dx.doi.org/10.1302/0301-620x.92b10.23495
  11. Dickson BC, Li S-Q, Wunder JS, Ferguson PC, Eslami B, Werier JA, et al. Giant cell tumor of bone express p63. Modern Pathology. 2008;21(4):369–75. Available from: http://dx.doi.org/10.1038/modpathol.2008.29
  12. Cheng D, Hu T, Zhang H, Huang J, Yang Q. Factors Affecting the Recurrence of Giant Cell Tumor of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center. Cellular Physiology and Biochemistry. 2015;36(5):1961–70. Available from: http://dx.doi.org/10.1159/000430164
  13. Han Y-H, Gao B, Huang J-H, Guo ZWZ, Jie Q, Yang L, et al. Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol . 2015;8(7):8446–52.
  14. Vijayakumaran R, Tan KH, Miranda PJ, Haupt S, Haupt Y. Regulation of Mutant p53 Protein Expression. Front Oncol. 2015;5:284. Available from: https://pubmed.ncbi.nlm.nih.gov/26734569
  15. Zhou Z, Li Y, Wang X, Hu J, Kuang M, Wang Z, et al. ALCAM(+) stromal cells: role in giant cell tumor of bone progression. Cell Death Dis. 2018;9(3):299. Available from: https://pubmed.ncbi.nlm.nih.gov/29463803
  16. Weidle UH, Eggle D, Klostermann S, Swart GWM. ALCAM/CD166: Cancer-related Issues. Cancer Genomics Proteomics. 2010;7:231–44.
  17. Donizy P, Zietek M, Halon A, Leskiewicz M, Kozyra C, Matkowski R. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients. Diagn Pathol. 2015;10:86. Available from: https://pubmed.ncbi.nlm.nih.gov/26134500
  18. Shi G, Jin Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther. 2010;1(5):39. Available from: https://pubmed.ncbi.nlm.nih.gov/21156086
  19. Zeineddine D, Hammoud AA, Mortada M, Boeuf H. The Oct4 protein: more than a magic stemness marker [Internet]. Vol. 3, Am J Stem Cells. 2014. Available from: www.AJSC.us/ISSN:2160-4150/AJSC0001509
  20. Mohiuddin IS, Wei S-J, Kang MH. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2019/03/21. 2020;1866(4):165432. Available from: https://pubmed.ncbi.nlm.nih.gov/30904611
  21. Ghaderi A, Abtahi S. Mesenchymal Stem Cells: Miraculous Healers or Dormant Killers? Stem Cell Rev Rep. 2018;14(5):722–33. Available from: http://dx.doi.org/10.1007/s12015-018-9824-y
  22. Kim Y, Nizami S, Goto H, Lee FY. Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg. 2012/05/17. 2012;4(2):107–16. Available from: https://pubmed.ncbi.nlm.nih.gov/22662295
  23. Purohit S, Pardiwala DN. Imaging of giant cell tumor of bone. Indian J Orthop. 2007;41(2):91–6. Available from: https://pubmed.ncbi.nlm.nih.gov/21139758
  24. Meyers SP. MRI of Bone and Soft Tissue Tumors and Tumorlike Lesions. Differential Diagnosis and Atlas. American Journal of Neuroradiology. 2008;30(1):e16–e16.
  25. Laning J, Borowski M, Giovino-Doherty M, Ji L, Shi M-J, Smith KP. Basic pluripotent stem cell culture protocols [Internet]. 2008. Available from: https://www.ncbi.nlm.nih.gov/books/NBK133258/
  26. Zhou Y, Chen D, Qi Y, Liu R, Li S, Zou H, et al. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis. Oncol Rep. 2017;37(6):3351–60. Available from: http://dx.doi.org/10.3892/or.2017.5617
  27. Xu L, Wu Z, Zhou Z, Yang X, Xiao J. Intratibial injection of patient-derived tumor cells from giant cell tumor of bone elicits osteolytic reaction in nude mouse. Oncol Lett. 2018/07/16. 2018;16(4):4649–55. Available from: https://pubmed.ncbi.nlm.nih.gov/30214599
  28. van der Heijden L, Dijkstra PDS, van de Sande MAJ, Kroep JR, Nout RA, van Rijswijk CSP, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014/04/09. 2014;19(5):550–61. Available from: https://pubmed.ncbi.nlm.nih.gov/24718514
  29. Wan-Ibrahim WI, Singh VA, Hashim OH, Abdul-Rahman PS. Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges. Mol Med. 2015/11/13. 2016;21(1):861–72. Available from: https://pubmed.ncbi.nlm.nih.gov/26581086
  30. Sanjay BK, Frassica FJ, Frassica DA, Unni KK, McLeod RA, Sim FH. Treatment of giant-cell tumor of the pelvis. The Journal of Bone & Joint Surgery. 1993;75(10):1466–75. Available from: http://dx.doi.org/10.2106/00004623-199310000-00007
  31. Hammas N, Laila C, Youssef ALM, Hind EF, Harmouch T, Siham T, et al. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Diagn Pathol. 2012;7:130. Available from: https://pubmed.ncbi.nlm.nih.gov/23016917
  32. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014/02/18. 2014;111(9):3514–9. Available from: https://pubmed.ncbi.nlm.nih.gov/24550495

How to Cite

Surachman, A. J. D. ., Kamal, A. F. ., Septelia, I. W. ., Siregar, N. C. ., Rahyussalim, Alida, R. H. ., & Dewi, S. S. . (2023). Immunohistochemical examination of recurrence and giant cell tumor specificity, is it correlated? cohort retrospective study. Bali Medical Journal, 13(1), 322–326. https://doi.org/10.15562/bmj.v13i1.4990

HTML
1

Total
0

Share

Search Panel

Achmad Jadi Didy Surachman
Google Scholar
Pubmed
BMJ Journal


Achmad Fauzi Kamal
Google Scholar
Pubmed
BMJ Journal


Inawati Wanandi Septelia
Google Scholar
Pubmed
BMJ Journal


Nurjati Chairani Siregar
Google Scholar
Pubmed
BMJ Journal


Rahyussalim
Google Scholar
Pubmed
BMJ Journal


Roswita Harahap Alida
Google Scholar
Pubmed
BMJ Journal


Soemarko Sumaryani Dewi
Google Scholar
Pubmed
BMJ Journal